Acute severe ulcerative colitis in children: A systematic review

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 440-449

  Turner, Dan ^a   Griffiths, Anne M ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

acute severe colitis; corticosteroids; cyclosporine; infliximab; pediatric ulcerative colitis; PUCAI; tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; NARCOTIC AGENT; OPIATE; PREDNISOLONE; TACROLIMUS;

AGE; ANAPHYLAXIS; CARDIOMYOPATHY; CHILDHOOD DISEASE; CLINICAL TRIAL; COLON; COLON RESECTION; CONVULSION; DIET RESTRICTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; FEMALE FERTILITY; GINGIVA HYPERTROPHY; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOMAGNESEMIA; INFECTION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MEGACOLON; META ANALYSIS; MORTALITY; OSTEOMYELITIS; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SEIZURE; SELF CONCEPT; SIDE EFFECT; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS;

ACUTE DISEASE; CHILD; COLITIS, ULCERATIVE; FEMALE; HUMANS;

EID: 78650166000     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21383     Document Type: Review

References (89)

1. Griffiths AM,. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004; 18: 509-523.
2. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology. 2007; 133: 423-432.
3. Moum B, Ekbom A, Vatn MH, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999; 94: 1564-1569.
4. Gulati R, Rawal KK, Kumar N, et al. Course of severe ulcerative colitis in northern India. Trop Gastroenterol. 1995; 16: 19-23.
5. Oshitani N, Kitano A, Fukushima R, et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion. 1990; 46: 107-113.
6. Chakravarty BJ,. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol. 1993; 88: 852-855.
7. Truelove SC, Jewell DP,. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974; 1: 1067-1070.
8. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 1987; 9: 50-54.
9. Kugathasan S, Dubinsky MC, Keljo D, et al. Severe colitis in children. J Pediatr Gastroenterol Nutr. 2005; 41: 375-385.
10. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103-110.
11. Barabino A, Tegaldo L, Castellano E, et al. Severe attack of ulcerative colitis in children: retrospective clinical survey. Dig Liver Dis. 2002; 34: 44-49.
12. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008; 57: 331-338.
13. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006; 4: 1118-1123.
14. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996; 129: 81-88.
15. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135: 1114-1122.
16. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2002; 16 (suppl 4): 7-12.
17. Edwards FC, Truelove SC,. The course and prognosis of ulcerative colitis. Gut. 1963; 4: 299-315.
18. Caprilli R, Viscido A, Latella G,. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 92-101.
19. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. Gastroenterology. 2009; 136 (5 suppl 1): A199.
20. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 1081-1088.
21. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955; 29: 1041-1048.
22. Brown SR, Haboubi N, Hampton J, et al. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008; 10 (suppl 3): 8-29.
23. Werlin SL, Grand RJ,. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology. 1977; 73 (4 Pt 1): 828-832.
24. Turner D, Mack DR, Uusoue K, et al. Prospective multicenter study of outcomes and predictors of response in severe pediatric ulcerative colitis. Gastroenterology. 2009; 136 (5 suppl 1): A571.
25. Turner D, Hyams J, Markowitz J, et al. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis. 2008;In press.
26. Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978; 2: 1086-1088.
27. Travis SPL, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn Colitis. 2008; 2: 24-62.
28. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339-344.
29. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology. 1980; 79: 1199-1204.
30. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut. 1986; 27: 481-485.
31. Scolapio JS,. The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease. J Clin Gastroenterol. 1999; 29: 223-224.
32. Benchimol EI, Turner D, Mann EH, et al. Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol. 2008; 103: 1524-1531.
33. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004; 19: 1079-1087.
34. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996; 38: 905-910.
35. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998; 10: 831-835.
36. Whorwell PJ, Isaacson P,. Toxic dilatation of colon in Crohn's disease. Lancet. 1981; 2: 1334-1337.
37. Berghouse LM, Elliott PR, Lennard-Jones JE, et al. Plasma prednisolone levels during intravenous therapy in acute colitis. Gut. 1982; 23: 980-983.
38. Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007; 102: 601-608.
39. Rosenberg W, Ireland A, Jewell DP,. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990; 12: 40-41.
40. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962; 2: 441-443.
41. Powell-Tuck J, Bown RL, Lennard-Jones JE,. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978; 13: 833-837.
42. Turner D, Kolho KL, Mack DR, et al. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 469-473.
43. Turner D, Mack DR, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010 [Epub ahead of print].
44. Gold DM, Levine JJ, Weinstein TA, et al. Prolonged medical therapy for severe pediatric ulcerative colitis. Am J Gastroenterol. 1995; 90: 732-735.
45. Jalan KN, Sircus W, Card WI, et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology. 1969; 57: 68-82.
46. Jones JH, Chapman M,. Definition of megacolon in colitis. Gut. 1969; 10: 562-564.
47. Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: a preliminary study. Gut. 1975; 16: 579-584.
48. Kumar S, Ghoshal UC, Aggarwal R, et al. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004; 19: 1247-1252.
49. Spicer CC, Buckell NA, Jones JE,. Prognosis in acute colitis. J R Coll Phys Lond. 1979; 13: 201-202.
50. Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004; 36: 21-28.
51. Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010; 97: 404-409.
52. Longobardi T, Bernstein CN,. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 731-743.
53. Bojic D, Radojicic Z, Nedeljkovic-Protic M, et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis. 2009; 15: 823-828.
54. Jakobovits SL, Travis SP,. Management of acute severe colitis. Br Med Bull. 2006; 75-76: 131-144.
55. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385.
56. Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol. 2002; 37: 29-34.
57. Turner D, Mack D, Uusoue K, et al. (eds.). A prospective multicenter study of outcomes and predictors of response in severe pediatric ulcerative colitis. World Congress of Gastroenterology Hepatology and Nutrition, Brazil; 2008.
58. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998; 85: 800-803.
59. Seetharamaiah R, West BT, Ignash SJ, et al. Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. J Pediatr Surg. 2009; 44: 1410-1417.
60. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007; 50: 1128-1138.
61. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005; 146: 35-40.
62. Castro M, Papadatou B, Ceriati E, et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg. 2007; 392: 161-164.
63. Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996; 22: 296-302.
64. Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 937-943.
65. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995; 38: 474-479.
66. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 1255-1262.
67. Sandborn WJ,. Is there a role for infliximab in the treatment of severe ulcerative colitis?: The American experience. Inflamm Bowel Dis. 2008; 14: S232-S233.
68. Lawson MM, Thomas AG, Akobeng AK,. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 3: CD005112.
69. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
70. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007; 26: 747-756.
71. Radford-Smith G, Croft A, Doecke J, et al. Outcomes of salvage therapy for acute severe ulcerative colitis: cyclosporin versus infliximab. Inflamm Bowel Dis. 2009; 15 (12 suppl): S43.
72. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008; 6: 1112-1116.
73. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab of severe ulcerative colitis. Gut. 2008; 57 (suppl II): A66.
74. Manosa M, Lopez San Roman A, Garcia-Planella E, et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion. 2009; 80: 30-35.
75. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007; 50: 1747-1753.
76. Socha P, Wawer Z, Ryzko J, et al. [Efficacy and safety of cyclosporine in the treatment of inflammatory bowel disease in children - a retrospective study.] Med Wieku Rozwoj. 2006; 10: 429-435.
77. Barabino A, Torrente F, Castellano E, et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther. 2002; 16: 1503-1507. (Pubitemid 34953591)
78. Benkov KJ, Rosh JR, Schwersenz AH, et al. Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994; 19: 290-294.
79. Treem WR, Davis PM, Hyams JS,. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr. 1991; 119: 994-997.
80. Kirschner BS, Whitington PF, Malfeo-Klein R,. Experience with cyclosporine A (CyA) in severe non-specific ulcerative colitis. Pediatr Res. 1989; 25: A117.
81. Navas Lopez VM, Blasco Alonso J, Sierra Salinas C, et al. [Safety and efficacy of oral tacrolimus in the treatment of paediatric inflammatory bowel disease.] An Pediatr (Barc). 2009; 70: 519-525.
82. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007; 45: 306-311.
83. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000; 137: 794-799.
84. Hyams JS, Lerer T, Griffiths AM, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010 [Epub ahead of print].
85. McGinnis JK, Murray KF,. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008; 42: 875-879.
86. Fanjiang G, Russell GH, Katz AJ,. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007; 44: 312-317.
87. Russell GH, Katz AJ,. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004; 39: 166-170.
88. Kugathasan S, Prajapati DN, Kim JP, et al. Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology. 2002; 122: A615.
89. Tolia V, Thomas R, Hyams J, et al. Multicenter review of infliximab use as a rescue therapy for pediatric ulcerative colitis (UC). J Pediatr Gastroenterol Nutr. 2003; 37: 339.